Unknown Manufacturer
Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.
用于改善2型糖尿病患者餐后高血糖(仅限用于经饮食、运动疗法不能有效控制血糖的患者或在饮食、运动疗法的基础上加用α-葡萄糖苷酶抑制剂后仍不能有效控制血糖的患者)。
2 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
